Prevalence of nasopharyngeal Streptococcus pneumoniae carriage and resistance to macrolides in the setting of azithromycin mass drug administration: analysis from a cluster-randomised controlled trial in Malawi, 2015-17

John D Hart, Lyson Samikwa, Harry Meleke, Sarah E Burr, Jen Cornick, Khumbo Kalua, Robin L Bailey, John D Hart, Lyson Samikwa, Harry Meleke, Sarah E Burr, Jen Cornick, Khumbo Kalua, Robin L Bailey

Abstract

Background: Azithromycin mass drug administration (MDA) could reduce child mortality. However, macrolide resistance, which has generally been reported to develop after whole-community MDA for trachoma control, is a concern, and it has less commonly been studied in the context of treating children to reduce mortality. Here, we report on macrolide resistance after biannual azithromycin MDA at the Malawi site of the MORDOR study.

Methods: In the MORDOR cluster-randomised trial in Malawi, 30 communities in Mangochi District were randomly selected. Communities were randomly assigned to receive azithromycin or placebo by simple randomisation without stratification. Children aged 1-59 months were administered azithromycin 20 mg/kg or placebo as an oral suspension biannually for a total of four treatments in 2015-17. 1200 children (40 children per community) were randomly selected for nasopharyngeal swabs at baseline, 12 months (6 months after the second treatment visit), and 24 months (6 months after the fourth treatment visit). Samples were processed to culture Streptococcus pneumoniae. The primary outcome was the proportion of S pneumoniae isolates exhibiting macrolide resistance at 12 months and 24 months, assessed in the intention-to-treat population. The study is registered with ClinicalTrials.gov, NCT02048007.

Findings: At baseline, 3467 (76%) of 4541 eligible children in the azithromycin group and 3107 (72%) of 4308 eligible children in the placebo group were treated. 564 nasopharyngeal swabs were taken from the azithromycin group and 563 from the placebo group, with similar numbers of swabs taken at 12 months and 24 months. In both groups at baseline, carriage of S pneumoniae was greater than 85% and the proportion of strains resistant to macrolides was 28%. At the 12-month follow-up, macrolide resistance was higher in the azithromycin group (36·9%, 95% CI 32·5-41·2) than in the placebo group (21·6%, 17·7-25·4; OR 2·26, 95% CI 1·46-3·49; p=0·0002). At 24 months, macrolide resistance remained higher in the azithromycin group (43·9%, 39·2-48·5) compared with placebo (32·8%, 28·5-37·1; OR 1·66, 1·15-2·40; p=0·0069).

Interpretation: These findings support previous evidence from trachoma MDA programmes and suggest that monitoring of macrolide resistance should remain a key component of azithromycin interventions for reducing child mortality.

Funding: Bill & Melinda Gates Foundation.

Conflict of interest statement

We declare no competing interests.

© 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Figures

Figure 1
Figure 1
Trial profile MDA=mass drug administration.
Figure 2
Figure 2
Distribution of macrolide resistance in Mangochi District at baseline Resistance is shown as a colour ramp, with intermediate percentages showing as shades of colour in between those shown in the legend.

References

    1. Schachter J, West SK, Mabey D, et al. Azithromycin in control of trachoma. Lancet. 1999;354:630–635.
    1. Fraser-Hurt N, Bailey RL, Cousens S, Mabey D, Faal H, Mabey DC. Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bull World Health Organ. 2001;79:632–640.
    1. Bowman RJC, Sillah A, Van Dehn C, et al. Operational comparison of single-dose azithromycin and topical tetracycline for trachoma. Invest Ophthalmol Vis Sci. 2000;41:4074–4079.
    1. Bailey RL, Arullendran P, Whittle HC, Mabey DC. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet. 1993;342:453–456.
    1. Mathew AA, Turner A, Taylor HR. Strategies to control trachoma. Drugs. 2009;69:953–970.
    1. Hart JD, Kalua K, Keenan JD, Lietman TM, Bailey RL. Cost-effectiveness of mass treatment with azithromycin for reducing child mortality in Malawi: secondary analysis from the MORDOR Trial. Am J Trop Med Hyg. 2020;103:1283–1290.
    1. Matzneller P, Krasniqi S, Kinzig M, et al. Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy. Antimicrob Agents Chemother. 2013;57:1736–1742.
    1. Emerson PM, Burton M, Solomon AW, Bailey R, Mabey D. The SAFE strategy for trachoma control: using operational research for policy, planning and implementation. Bull World Health Organ. 2006;84:613–619.
    1. Fry AM, Jha HC, Lietman TM, et al. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clin Infect Dis. 2002;35:395–402.
    1. Coles CL, Levens J, Seidman JC, Mkocha H, Munoz B, West S. Mass distribution of azithromycin for trachoma control is associated with short-term reduction in risk of acute lower respiratory infection in young children. Pediatr Infect Dis J. 2012;31:341–346.
    1. Coles CL, Seidman JC, Levens J, Mkocha H, Munoz B, West S. Association of mass treatment with azithromycin in trachoma-endemic communities with short-term reduced risk of diarrhea in young children. Am J Trop Med Hyg. 2011;85:691–696.
    1. Sadiq ST, Glasgow KW, Drakeley CJ, et al. Effects of azithromycin on malariometric indices in The Gambia. Lancet. 1995;346:881–882.
    1. Hart JD, Edwards T, Burr SE, et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Trop Med Int Health. 2014;19:207–211.
    1. Porco TC, Gebre T, Ayele B, et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA. 2009;302:962–968.
    1. Keenan JD, Bailey RL, West SK, et al. Azithromycin to reduce childhood mortality in sub-Saharan Africa. N Engl J Med. 2018;378:1583–1592.
    1. Porco TC, Hart J, Arzika AM, et al. Mass oral azithromycin for childhood mortality: timing of death after distribution in the MORDOR trial. Clin Infect Dis. 2019;68:2114–2116.
    1. Oldenburg CE, Arzika AM, Maliki R, et al. Optimizing the number of child deaths averted with mass azithromycin distribution. Am J Trop Med Hyg. 2020;103:1308–1310.
    1. WHO WHO guideline on mass drug administration of azithromycin to children under five years of age to promote child survival. 2020.
    1. Coles CL, Mabula K, Seidman JC, et al. Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment. Clin Infect Dis. 2013;56:1519–1526.
    1. Skalet AH, Cevallos V, Ayele B, et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial. PLoS Med. 2010;7
    1. Leach AJ, Shelby-James TM, Mayo M, et al. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis. 1997;24:356–362.
    1. Althouse BM, Hammitt LL, Grant L, et al. Identifying transmission routes of Streptococcus pneumoniae and sources of acquisitions in high transmission communities. Epidemiol Infect. 2017;145:2750–2758.
    1. Doan T, Arzika AM, Hinterwirth A, et al. Macrolide resistance in MORDOR I—a cluster-randomized trial in Niger. N Engl J Med. 2019;380:2271–2273.
    1. Bloch EM, Coles CL, Kasubi M, et al. Biannual treatment of preschool children with single dose azithromycin to reduce mortality: Impact on azithromycin resistance in the MORDOR trial in Tanzania. Am J Trop Med Hyg. 2020;103:1301–1307.
    1. Schito GC, Felmingham D. Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999-2003) Int J Antimicrob Agents. 2005;26:479–485.
    1. Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci USA. 1999;96:1152–1156.
    1. Clinical and Laboratory Standard Institute . 30th edn. Clinical and Laboratory Standard Institute; Wayne, PA: 2020. Performance standards for antimicrobial disk susceptibility tests.
    1. Hart JD, Samikwa L, Sikina F, et al. Effects of biannual azithromycin mass drug administration on malaria in Malawian children: a cluster-randomized trial. Am J Trop Med Hyg. 2020;103:1329–1334.
    1. Hart JD, Kalua K, Keenan JD, Lietman TM, Bailey RL. Effect of mass treatment with azithromycin on causes of death in children in Malawi: secondary analysis from the MORDOR trial. Am J Trop Med Hyg. 2020;103:1319–1328.
    1. Yomo A, Subramanyam VR, Fudzulani R, et al. Carriage of penicillin-resistant pneumococci in Malawian children. Ann Trop Paediatr. 1997;17:239–243.
    1. Ready D, Lancaster H, Qureshi F, Bedi R, Mullany P, Wilson M. Effect of amoxicillin use on oral microbiota in young children. Antimicrob Agents Chemother. 2004;48:2883–2887.
    1. Gaynor BD, Holbrook KA, Whitcher JP, et al. Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year. Br J Ophthalmol. 2003;87:147–148.
    1. Gaynor BD, Chidambaram JD, Cevallos V, et al. Topical ocular antibiotics induce bacterial resistance at extraocular sites. Br J Ophthalmol. 2005;89:1097–1099.
    1. Batt SL, Charalambous BM, Solomon AW, et al. Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother. 2003;47:2765–2769.
    1. Burr SE, Milne S, Jafali J, et al. Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross-sectional surveys in The Gambia. Bull World Health Organ. 2014;92:490–498.
    1. Haug S, Lakew T, Habtemariam G, et al. The decline of pneumococcal resistance after cessation of mass antibiotic distributions for trachoma. Clin Infect Dis. 2010;51:571–574.
    1. Ho DK-H, Sawicki C, Grassly N. Antibiotic resistance in Streptococcus pneumoniae after azithromycin distribution for trachoma. J Trop Med. 2015;2015
    1. Kalua K, Chisambi A, Chinyanya D, et al. One round of azithromycin MDA adequate to interrupt transmission in districts with prevalence of trachomatous inflammation—follicular of 5·0–9·9%: evidence from Malawi. PLoS Negl Trop Dis. 2018;12
    1. Torres NF, Solomon VP, Middleton LE. Patterns of self-medication with antibiotics in Maputo city: a qualitative study. Antimicrob Resist Infect Control. 2019;8:161.
    1. Torres NF, Solomon VP, Middleton LE. Identifying the commonly used antibiotics for self-medication in urban Mozambique: a qualitative study. BMJ Open. 2020;10
    1. Beceiro A, Tomás M, Bou G. Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world? Clin Microbiol Rev. 2013;26:185–230.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit